Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis
نویسندگان
چکیده
منابع مشابه
FK 506: a new therapeutic agent for severe recalcitrant psoriasis.
BETWEEN 12 and 18 months ago we treated three patients with FK S06 who had severe psoriasis that was refractory to conventionai therapy and four patients with w,despread incidental psonasis before undergoing hean or liver transplantation under FK 506. All had dramatic resolution of psonasis. which remaIned in remission as long as full-dose therapy was provided. Serial skin biopsies had a rapid ...
متن کاملTacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis.
BACKGROUND Psoriasis, a disease of unknown etiology, is in some patients severe, extremely debilitating, and unresponsive to conventional therapies, including UV-B, oral psoralen with long-wave UV radiation in the A range (PUVA), oral retinoids, and methotrexate. We report the results from our study of seven patients with refractory psoriasis who were treated with the new immunosuppressive drug...
متن کاملMaculopathy Associated with Tacrolimus (FK 506)
A 63-year-old man with a history of liver transplantation presented to our clinic complaining of visual disturbance. He had been receiving tacrolimus (FK 506) for 30 months (6 mg/day for 2 years and 3 mg/day for 6 months); he reported that the visual disturbance began while taking tacrolimus. A full ophthalmologic examination and electrophysiologic and imaging studies were performed. The best c...
متن کاملTacrolimus ( FK 506 ) and the Pharmaceuticall Academid Regulatory Gauntlet
• The pivotal Issue of transplant rejection diagnosis and management Is design, conduct, and analysis of clinical trials. The historical experience with clinical trials of major immunosuppressive drugs (cyclosporine and especially tacrollmus) Is examined in this article. Cyclosporlne was a turning point In transplantation, providing an extraordinary Improvement over previous therapies. Addition...
متن کاملTacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial.
Primary sclerosing cholangitis (PSC) is a chronic inflammatory disease of the liver that is characterized by progressive cholestasis and the development of secondary biliary cirrhosis. There is no widely recognized therapy for this disease, although anti-inflammatory agents (steroids), immunosuppressive agents (methotrexate), anti-fibrotics (colchicine), and choleretic agents (ursodeoxycholic a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Archives of Dermatology
سال: 1992
ISSN: 0003-987X
DOI: 10.1001/archderm.128.6.781